[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"relapsed-multiple-myeloma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:relapsed-multiple-myeloma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,65,88,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100549432","phase-1-study-to-assess-safety-and-tolerability-of-opn-6602-in-subjects-with-relapsed-andor-refractory-multiple-myeloma-100549432",false,"NCT06433947","Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and\u002For Refractory Multiple Myeloma","A Phase 1b, Dose Escalation\u002FDose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and\u002For Refractory Multiple Myeloma","Inclusion Criteria:\n\n* Confirmed diagnosis of multiple myeloma (MM)\n* Relapsed or refractory to 3 or more different prior lines of therapy for MM that included immunomodulatory agents, proteosome inhibitors, and anti-CD38 antibody and not a candidate for or intolerant to established therapy known to provide clinical benefit\n* Adequate hematologic, renal, liver, cardiac function\n\nExclusion Criteria:\n\n* Monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, Waldenström's macroglobulinemia, or IgM myeloma\n* Active plasma cell leukemia\n* Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes (POEMS syndrome)\n* Prior Stevens Johnson syndrome\n* Localized radiation therapy to disease site(s) within 2 weeks of the first dose\n* Prior autologous peripheral stem cell transplant or prior autologous bone marrow transplantation within \\\u003C90 days of the first dose of study drug\n* Prior allogeneic stem cell transplantation or solid organ transplantation within 12 months of first dose of study drug; subjects receiving immunosuppressive medication for active graft vs host disease will be excluded.\n* Prior chemotherapy, targeted anticancer or radiation therapy within 2 weeks prior to first dose of study drug\n* Concomitant high-dose corticosteroids (except subjects on chronic steroids given for disorders other than myeloma)\n* Known central nervous system involvement by multiple myeloma\n* Active known second malignancy with exception of adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer; adequately treated Stage 1 cancer from which the subject is currently in remission and has been in remission for ≥2 years; low-risk prostate cancer with a Gleason score \\\u003C7 and a PSA level \\\u003C10 ng\u002FmL; any other cancer from which the subject has been disease-free for ≥3 years\n* Ongoing systemic infection requiring parenteral treatment\n* Poorly controlled Type 2 diabetes","ALL","18 Years",{"count":19,"type":20},130,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and\u002For refractory MM.",[26,27],"Relapsed Multiple Myeloma","Refractory Multiple Myeloma","RECRUITING","2026-05-15",{"date":31,"type":32},"2026-05-19","ACTUAL",{"date":34,"type":32},"2024-08-22",{"date":36,"type":20},"2026-07",{"name":38,"class":39},"Opna Bio LLC","INDUSTRY",12,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100542841","phase-1-talquetamab-in-combination-with-iberdomide-and-dexamethasone-for-relapsed-or-refractory-multiple-myeloma-100542841","NCT06348108","Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma","A Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","Inclusion Criteria:\n\n1. Male or female ≥ 18 years of age.\n2. Has a prior history of (h\u002Fo) MM (based on International Myeloma Working Group (IMWG) criteria) and now has evidence of relapsed or refractory MM. RRMM of progressive disease as defined by the IMWG 2006 and 2016 criteria (Kumar at al).\n3. Specific criteria for dose escalation and dose expansion:\n\n   1. Phase 1 dose escalation: patients will be required to have TCE RRMM (including a proteasome inhibitor (PI) (≥ 2 cycles or 2 months of treatment), an immunomodulatory drug (IMiD)) (≥ 2 cycles or 2 months of treatment) and a CD38 antibody (≥ 2 cycles or 2 months of treatment) after receiving ≥ 3 prior lines of therapy. Prior BCMA exposure is allowed. (Subjects with discontinued PI\u002FIMiD\u002FCluster of differentiation 38 (CD38) therapy due to severe adverse event after \\\u003C 2 months are allowed)\n   2. Dose expansion cohort: RRMM patients will be lenalidomide refractory, TCE (exposed to IMiD, PI and CD38 antibody therapy (≥ 2 cycles or 2 months of treatment for each) and have received ≥ 2 prior lines of therapy. Prior BCMA targeted therapy is allowed, not required. (Subjects with discontinued PI\u002FIMiD\u002FCD38 therapy due to severe adverse event after \\\u003C 2 months are allowed. Lenalidomide refractory is defined as having evidence of progressive disease on lenalidomide (≥ 10 mg or greater, ≥ 21 days\u002F28) or within 60 days of stopping lenalidomide therapy.)\n4. Has measurable disease defined as at least 1 of the following:\n\n   1. Serum M-protein ≥ 0.5 g\u002FdL (dose escalation) and 1.0 g\u002FdL (dose expansion cohorts)\n   2. Urine M-protein ≥ 200 mg\u002F24 hours\n   3. Serum free light chain (FLC) assay: involved FLC assay ≥ 10 mg\u002FdL (≥ 100 mg\u002FL) AND an abnormal serum FLC ratio (\\\u003C 0.26 or \\> 1.65). (Can be used to fulfill the inclusion criteria of measurable disease in patients who do not have measurable disease by M-protein).\n5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n6. Has adequate baseline organ function, as demonstrated by the following:\n\n   1. Calculated creatinine clearance \\> 30 mL\u002Fmin as assessed by the Cockcroft-Gault equation, Modification of Diet in Renal Disease (MDRD) equation (National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 2015) or as assessed by 24-hour urine collection.\n   2. Serum bilirubin ≤ 1.5 mg\u002FdL, excluding Gilbert's.\n   3. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × institutional upper limit normal (ULN).\n   4. Total serum calcium (corrected for serum albumin) or ionized calcium within normal limits (WNL) (treatment of hypercalcemia is allowed and patients may enroll if hypercalcemia returns to WNL with standard treatment).\n7. Has adequate baseline hematologic function, as demonstrated by the following:\n\n   1. Absolute neutrophil count (ANC) ≥ 1.0 x 10\\^9\u002FL (myeloid growth factors must not have been administered within 7 days (14 days for extended 1\u002F2-life products).\n   2. Hemoglobin ≥ 8 g\u002FdL (red blood cell transfusions permitted provided the anemia is disease-related).\n   3. Platelet count ≥ 100 x 10\\^9\u002FL and no platelet transfusions during the 7 days before first dose (without transfusions). (Dose expansion cohorts will be allowed to have platelets counts ≥ 75 x 10\\^9\u002FL with no platelet transfusions during the prior 7 days).\n8. Must have at least 2 negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test result obtained prior to initiating therapy. The first test should be performed within 10-14 days and the second within 24 hours prior to initiating therapy if the patient is a female of childbearing potential (FCBP; defined as a sexually mature woman who has not undergone a hysterectomy or bilateral oophorectomy or has not been naturally postmenopausal for at least 24 consecutive months).\n9. Men and women of childbearing potential must agree to not donate sperm and eggs (ova and oocytes) throughout study therapy and for 3 months after the last treatment.\n10. Men and women agree to use acceptable contraceptive methods for the duration of time on the study, and continue to use acceptable contraceptive methods for 3 months after the last treatment with study treatment.\n\n    1. Women of childbearing potential must agree to 2 methods of reliable birth control simultaneously while receiving study treatment and until 100 days after last dose of study treatment: one highly effective form of contraception (tubal ligation, intrauterine device, hormonal \\[oral, injectable, transdermal patches, vaginal rings or implants\\] or partner's vasectomy, and 1 additional effective contraceptive method (male latex or synthetic condom, diaphragm or cervical cap).\n    2. Males must agree to always use a latex or synthetic condom during any sexual contact with females of reproductive potential.\n11. All patients should be encouraged to be fully vaccinated prior to initiation of therapy including being up-to-date on vaccines against pneumococcus, yearly influenza, Coronavirus disease (COVID) booster(s), and any age appropriate vaccine. Live attenuated vaccines are not allowed while on study treatment or within 4 weeks of starting treatment.\n12. Has provided signed informed consent before initiation of any study-specific procedures or treatment.\n13. Must agree to, and be capable of, adhering to the study visit schedule and other protocol requirements, including follow-up for overall survival.\n\nExclusion Criteria:\n\n1. Has persistent clinically significant toxicities (grade ≥ 2; per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0) from previous anticancer therapy (excluding alopecia which is permitted and excluding grades 2 and 3 laboratory abnormalities (including hematologic abnormalities) if participants are not associated with symptoms, are not considered clinically significant by the investigator, and can be managed with available medical therapies.\n2. Has NCI CTCAE grade ≥ 3 peripheral neuropathy from any etiology or grade ≥ 2 peripheral neuropathy with pain.\n3. Has received treatment with cytotoxic (alkylators) within 3 weeks, biologic (IMiDs\u002FPIs) within 2 weeks, targeted therapies (monoclonal antibodies) within 4 weeks, chimeric antigen receptor (CAR) T-cell (CAR-T)or autologous stem cell transplant therapy within 3 months or any novel therapy within 5- 1\u002F2 lives of therapy.\n4. Has had radiation therapy within 14 days of first dose of study therapy, unless less than 5% marrow exposure, then no limit.\n5. Has had any prior GPRC5D targeted bispecific antibody therapy or GPRC5D CAR-T therapy or has had previous treatment with Iber.\n6. Has any active or uncontrolled infection including any viral, bacterial or fungal infection; and\u002For HIV, active hepatitis (Hep) C and active Hep B (hepatitis B (HB) surface antigen (HBsAg) (+), HB core antigen (HBcAb) (+) or (+) Hep B deoxyribonucleic acid (DNA) by polymerase chain reaction (pcr), Hep C ribonucleic acid (RNA) (+) by pcr. Patients who have received Intravenous immunoglobulin therapy (IVIG) replacement therapy may have (+) HBcAb results from the IVIG therapy. These patients can enroll if Hep B DNA by pcr test is negative. These patients need to be on antiviral therapy and be monitored for hepatitis B virus (HBV) DNA throughout study therapy per local guidelines and as clinically indicated.\n7. Has an additional active malignancy that may confound the assessment of the study endpoints. If the patient has a past cancer history (active malignancy within 2 years before study entry) with substantial potential for recurrence, this must be discussed with the sponsor\u002Finvestigator before study entry. Patients with the following concomitant neoplastic diagnoses are eligible: nonmelanoma skin cancer and carcinoma in situ (including transitional cell carcinoma, cervical cancer, anal carcinoma, ductal carcinoma in situ (DCIS) and melanoma in situ), any cancer resected with curative intent, low-grade cancer not requiring therapy.\n8. Is pregnant or breast feeding.\n9. Has clinically significant cardiovascular disease including, albeit not limited to:\n\n   1. Uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure\n   2. Uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months before study entry\n   3. Uncontrolled hypertension or clinically significant arrhythmias not controlled by medication.\n10. Has active POEMS (polyneuropathy, organomegaly, endocrinopathy\u002Fedema, monoclonal-protein, skin syndrome), amyloid light (AL) amyloidosis, primary plasma cell leukemia or active central nervous system (CNS) or parenchymal\u002Fleptomeningeal myeloma.\n11. Has uncontrolled, clinically significant organ dysfunction that in the opinion of the investigator would put the patient at significant risk for toxicity from study therapy.\n12. Has recent major surgery within 4 weeks or significant gastrointestinal (GI) disease that would interfere with GI absorption of oral medications.\n13. Has a condition, including autoimmune disease, requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days before study therapy administration. Inhaled or topical steroids and adrenal replacement doses \\\u003C10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.\n14. Has received treatment with allogeneic stem cell transplant within 6 months before the first dose of study treatment and if \\> 6 months from allogeneic stem cell transplantation (alloSCT) must be off all immunosuppression and without evidence of active graft-versus-host disease (GVHD).\n15. Uncontrolled epilepsy or new\u002Frecent seizure activity within 6 months of study entry.\n16. Live vaccine administered within 4 weeks prior to study therapy.",{"count":49,"type":20},32,[23],"This phase I trial will evaluate the safety, side effects, and best dose of talquetamab in combination with iberdomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). There is currently a significant unmet need for patients with relapsed or refractory multiple myeloma (RRMM) who are triple class refractory and have been exposed to B-cell maturation antibody (BCMA) targeted therapy. These patients currently have limited treatment options and poor survival. Talquetamab is an FDA approved drug that can bring T-cells to the myeloma cell, resulting in myeloma cell death. Iberdomide is an investigational drug and works by targeting and destroying proteins that help myeloma cancer cells to survive. Dexamethasone is a corticosteroid, is similar to a natural hormone produced by the adrenal glands to reduce inflammation (swelling, heat, redness, and pain) and is used to in helping to treat certain types of cancer including myeloma.",[53,27,26],"Multiple Myeloma","2026-03-11",{"date":56,"type":32},"2026-03-13",{"date":58,"type":32},"2025-07-28",{"date":60,"type":20},"2029-07-31",{"name":62,"class":63},"Alfred Chung, MD","OTHER",1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":64},"100508117","phase-2-iberdomide-daratumumab-carfilzomib-and-dexamethasone-iber-kdd-in-patients-with-relapsedrefractory-multiple-myeloma-100508117","NCT05896228","Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed\u002FRefractory Multiple Myeloma","Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed\u002FRefractory Multiple Myeloma","Iber-KDd","Inclusion Criteria:\n\n1. Patients with histologically confirmed MM with progressive disease according to the IMWG criteria 47 during or within 60 days of their last regimen who have received 1-3 lines of prior therapy (inclusive of a lenalidomide-containing regimen) and have measurable disease within 4 weeks of enrollment based on one of the following:\n\n   * Serum monoclonal protein ≥ 1.0 g\u002FdL\n   * Urine monoclonal protein ≥ 200 mg\u002F24 hour\n   * Involved serum immunoglobulin free light chains (FLC) ≥ 10 mg\u002FdL AND abnormal kappa\u002Flambda ratio.\n\n   Note: Because the primary endpoint is MRD-negativity rate, per the discretion of the Principal Investigator (PI), patients without measurable disease (e.g., M-spike \\\u003C 1.0 g\u002FdL) may also be enrolled in line with the IMWG MM response criteria 47.\n2. Prior treatment with cluster of differentiation 38 (CD38) -directed therapy is permitted only if all the following are fulfilled:\n\n   * Best response achieved during CD38-directed therapy was ≥ PR.\n   * Patient did not progress while receiving CD38-directed therapy or within 60 days of last dose of therapy.\n   * Patient did not discontinue CD38-directed therapy due to a related AE.\n3. Prior treatment with carfilzomib is permitted only if all the following are fulfilled:\n\n   * Best response achieved during carfilzomib-based therapy was ≥ PR.\n   * Patient did not progress while receiving carfilzomib-based therapy or within 60 days of last dose of therapy.\n   * Patient did not discontinue carfilzomib due to a related AE.\n4. Creatinine Clearance (CrCl) ≥60 ml\u002Fmin measured within 4 weeks of enrollment. CrCl can be measured or estimated using Cockcroft-Gault method, Modification of Diet in Renal Disease (MDRD), or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulae.\n5. Age ≥ 18 years at the time of signing the informed consent documentation. Age limit of 75 years.\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 within 4 weeks of enrollment (Appendix A).\n7. Absolute neutrophil count (ANC) ≥ 1.0 K cells\u002FµL, hemoglobin ≥ 8 g\u002FdL, and platelet count ≥ 50 K platelets\u002FµL measured within 4 weeks of enrollment unless cytopenias are deemed to be due to disease at the discretion of the clinical Investigator. Transfusions and administration of growth factors are permissible.\n8. Adequate hepatic function with bilirubin \\\u003C 1.5 x the upper limit of normal (ULN) and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 3.0 x ULN measured within 4 weeks of enrollment.\n9. All study participants must be able to tolerate one of the following thromboprophylactic strategies: oral factor Xa inhibitors or low molecular weight heparin or alternative anti-coagulant.\n10. Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test within 10-14 days and again within 24 hours prior to prescribing of iberdomide for Cycle 1 (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective (barrier) method, at the same time at least 28 days before she starts taking iberdomide without interruption. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.\n\n    * A FCBP is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). Females who do not meet the above definition of FCBP should be classified as females not of childbearing potential (FNCBP).\n\nExclusion Criteria:\n\n1. Patients receiving concurrent systemic treatment for MM with the following exceptions:\n\n   * Treatment of hypercalcemia or spinal cord compression or aggressively progressing myeloma with current or prior corticosteroids is permitted.\n   * Patients may receive kyphoplasty\u002Fvertebroplasty for symptomatic vertebral compression fractures.\n   * Bone targeting agents are permitted.\n   * Concurrent or prior treatment with corticosteroids for indications other than MM is permitted.\n   * Focal radiation therapy within 14 days prior to randomization with the exception of palliative radiotherapy for symptomatic management but not on measurable extramedullary plasmacytoma.\n   * Prior MM treatments must be concluded with a washout period of 2 weeks from last dose.\n2. Patients who are refractory to an anti-CD38-directed regimen:\n\n   * Prior anti-CD38-directed therapy and carfilzomib are permitted as long as above inclusion criteria are met.\n3. Patients with plasma cell leukemia.\n4. Patients with Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes syndrome (POEMS syndrome).\n5. Patients with amyloidosis.\n6. Patients with known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) \\\u003C 50% of predicted normal within 4 weeks of enrollment.\n\n   Note: FEV1 testing is required for patients suspected of having COPD, and patients must be excluded if FEV1 \\\u003C 50% of predicted normal at any time during the study.\n7. Pregnant or lactating females. Because there is a potential risk for AEs in nursing infants secondary to treatment of the mother with carfilzomib in combination with iberdomide, pregnant or lactating females are excluded from study participation. These potential risks may also apply to other agents used in this study.\n8. Uncontrolled hypertension (ie, systolic blood pressure \\[BP\\] \\> 160 mmHg, diastolic BP \\> 100 mmHg) or diabetes\n9. Patients with active hepatitis B or C infection.\n10. Patient is:\n\n    * Seropositive for human immunodeficiency virus (HIV) (Section 10.3.5.1) within 4 weeks of enrollment.\n    * Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen \\[HBsAg\\]) within 4 weeks of enrollment. Patients with resolved infection (i.e., patients who are HBsAg negative but positive for antibodies to hepatitis B core antigen (anti-HBc) and\u002For antibodies to hepatitis B surface antigen \\[anti-HBs\\]) must be screened using real-time polymerase chain reaction (RT-PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Patients with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination do not need to be tested for HBV DNA by PCR.\n    * Seropositive for hepatitis C (except in the setting of a sustained virologic response (SVR), defined as aviremia at least 12 weeks after completion of antiviral therapy).\n\n    For more information regarding the timing and frequency of hepatitis testing, refer to Section 10.3.5.1.\n11. Significant cardiovascular disease with New York Heart Association (NYHA) class III or IV symptoms, symptomatic ischemia, current uncontrolled arrhythmias, screening electrocardiogram (ECG) with corrected QT interval (QTc) of \\> 470 msec within 4 weeks of enrollment, pericardial disease, or myocardial infarction within 4 months prior to enrollment, and left ventricular ejection fraction (EF) \\\u003C 40% as assessed by transthoracic echocardiogram (ECHO) within 4 weeks of enrollment. Current unstable angina as determined by history and physical exam, hypertrophic cardiomyopathy or restrictive cardiomyopathy\n12. Pulmonary hypertension\n13. Has refractory gastrointestinal (GI) disease with refractory nausea\u002Fvomiting, inflammatory bowel disease, or bowel resection that would prevent absorption of oral agents\n14. Uncontrolled intercurrent illness including but not limited to active infection or psychiatric illness\u002Fsocial situations that would compromise compliance with study requirements\n15. Significant neuropathy ≥ Grade 3 with pain at baseline\n16. Contraindication to any concomitant medication, including antivirals or anticoagulation\n17. Major surgery within 3 weeks prior to first dose\n18. Prior treatment with iberdomide\n19. For female patients: Patient plans to become pregnant or donate eggs during the Treatment Period and\u002For required period for contraception use post-last dose of study treatment.\n20. For male patients: Patient plans to father a child or donate sperm during the Treatment Period and\u002For required period for contraception use post-last dose of study treatment.\n21. Patients with limited decision-making capacity.","75 Years",{"count":75,"type":20},30,[77],"PHASE2","The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.",[27,26],"2026-03-09",{"date":54,"type":32},{"date":83,"type":32},"2024-02-20",{"date":85,"type":20},"2031-03-01",{"name":87,"class":63},"Benjamin T Diamond, MD",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":108,"leadSponsor":110,"locationsCount":64},"100600173","phase-4-immunoglobulins-in-multiple-myeloma-patients-receiving-a-bcma-directed-t-cell-engager-100600173","NCT07094048","Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager","CHUQUL_HO001","Inclusion Criteria:\n\n* Multiple myeloma patient:\n* ≥ 18 years old\n* ≥ 1 prior lines of therapy\n* Receiving a BCMA-directed T-cell Engager therapy (starting on treatment)\n* On previous Ig support or not\n\nExclusion Criteria:\n\n* Less than 18 years old\n* Pregancy or breastfeeding",{"count":96,"type":20},80,[98],"PHASE4","Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.",[101,26],"Multiple Myeloma Refractory",[103,53],"Immunoglobulins","2026-01-05",{"date":106,"type":32},"2026-01-07",{"date":104,"type":32},{"date":109,"type":20},"2029-12",{"name":111,"class":63},"CHU de Quebec-Universite Laval",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":122,"conditions":123,"keywords":128,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":40},"100525280","phase-1-idp-023-as-a-single-agent-and-in-combination-with-antibody-therapies-in-patients-with-advanced-hematologic-cancers-100525280","NCT06119685","IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","Phase 1\u002F2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","Key Inclusion Criteria:\n\n* For MM patients: Documented diagnosis of MM requiring systemic therapy and relapsed and\u002For refractory (R\u002FR) disease after ≥ 3 prior lines of therapy.\n* For NHL patients: R\u002FR disease and failed ≥ 2 lines of systemic chemotherapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy of greater than 12 weeks per the Investigator.\n\nKey Exclusion Criteria:\n\n* Impaired cardiac function or history of clinical significant cardiac disease.\n* Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.\n* Active SARS-CoV-2 infection.\n* Has untreated central nervous system, epidural tumor metastasis, or brain metastasis.",{"count":120,"type":20},128,[23,77],"This is an open label, Phase 1\u002F2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.",[124,53,125,126,127,27,26],"NHL","Blood Cancer","Refractory Non-Hodgkin Lymphoma","Relapsed Non-Hodgkin Lymphoma",[129],"Advanced Hematologic Cancers","2025-05-30",{"date":132,"type":32},"2025-06-03",{"date":134,"type":32},"2023-10-25",{"date":136,"type":20},"2029-12-31",{"name":138,"class":39},"Indapta Therapeutics, INC."]